pchk1 Search Results


rabbit pab specific for pchk1 phosphorylated on ser345 gtx100065 antibody  (Gentex Corporation)
90
Gentex Corporation rabbit pab specific for pchk1 phosphorylated on ser345 gtx100065 antibody
Rabbit Pab Specific For Pchk1 Phosphorylated On Ser345 Gtx100065 Antibody, supplied by Gentex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit pab specific for pchk1 phosphorylated on ser345 gtx100065 antibody/product/Gentex Corporation
Average 90 stars, based on 1 article reviews
rabbit pab specific for pchk1 phosphorylated on ser345 gtx100065 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lovo tumor ic 80 pchk1(ser345  (GraphPad Software Inc)
90
GraphPad Software Inc lovo tumor ic 80 pchk1(ser345
RP-3500 is efficacious as a single agent in ATM-deficient tumor models. A, LoVo tumor xenograft volume in mice treated with RP-3500 orally once daily × 17 days. Results are expressed as mean ± SEM, N = 10/group. a One mouse sacrificed due to body weight loss on day 12. B, Tumor volume of a human gastric cancer PDX A with a biallelic loss of ATM in mice treated with RP-3500 at 5 and 10 mg/kg once daily x 28 days. Results expressed as mean ± SEM, N = 10/group. Statistical significance relative to vehicle control for A and B established by one-way ANOVA with Fisher LSD test; ** P < 0.01; **** P < 0.0001. C, Proportion of <t>pCHK1</t> <t>(Ser345)</t> inhibition relative to circulating free RP-3500 plasma levels. Tumors and plasma sampled at 1 and 3 hours after RP-3500 administration. The pCHK1/total CHK1 signal is represented relative to vehicle-treated tumors. D, Free circulating plasma concentrations of RP-3500 over time in SCID mice. Green, measured concentrations; red, simulated PK at 5 mg/kg. Horizontal line indicates in vivo LoVo tumor pCHK1 <t>IC</t> <t>80</t> determined by nonlinear curve fit of C . Vertical grey bar indicates window of duration over IC 80 at the MED (5–7 mg/kg). h, hours. E, pKAP1 (Ser824) in LoVo tumors from mice treated with RP-3500 once daily x 7 days and harvested 24 hours after the last dose. pKAP1/total KAP1 quantified by immunoblot are represented as fold increase over vehicle control signal. F, Quantitative γH2AX and pKAP1 staining of tissue sections from the gastric PDX-bearing mice treated with RP-3500 once daily for 3 days harvested 24 hours after the last dose. PD, pharmacodynamics.
Lovo Tumor Ic 80 Pchk1(Ser345, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lovo tumor ic 80 pchk1(ser345/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
lovo tumor ic 80 pchk1(ser345 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-pchk1  (ABclonal Biotechnology)
90
ABclonal Biotechnology anti-pchk1
RP-3500 is efficacious as a single agent in ATM-deficient tumor models. A, LoVo tumor xenograft volume in mice treated with RP-3500 orally once daily × 17 days. Results are expressed as mean ± SEM, N = 10/group. a One mouse sacrificed due to body weight loss on day 12. B, Tumor volume of a human gastric cancer PDX A with a biallelic loss of ATM in mice treated with RP-3500 at 5 and 10 mg/kg once daily x 28 days. Results expressed as mean ± SEM, N = 10/group. Statistical significance relative to vehicle control for A and B established by one-way ANOVA with Fisher LSD test; ** P < 0.01; **** P < 0.0001. C, Proportion of <t>pCHK1</t> <t>(Ser345)</t> inhibition relative to circulating free RP-3500 plasma levels. Tumors and plasma sampled at 1 and 3 hours after RP-3500 administration. The pCHK1/total CHK1 signal is represented relative to vehicle-treated tumors. D, Free circulating plasma concentrations of RP-3500 over time in SCID mice. Green, measured concentrations; red, simulated PK at 5 mg/kg. Horizontal line indicates in vivo LoVo tumor pCHK1 <t>IC</t> <t>80</t> determined by nonlinear curve fit of C . Vertical grey bar indicates window of duration over IC 80 at the MED (5–7 mg/kg). h, hours. E, pKAP1 (Ser824) in LoVo tumors from mice treated with RP-3500 once daily x 7 days and harvested 24 hours after the last dose. pKAP1/total KAP1 quantified by immunoblot are represented as fold increase over vehicle control signal. F, Quantitative γH2AX and pKAP1 staining of tissue sections from the gastric PDX-bearing mice treated with RP-3500 once daily for 3 days harvested 24 hours after the last dose. PD, pharmacodynamics.
Anti Pchk1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pchk1/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
anti-pchk1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


RP-3500 is efficacious as a single agent in ATM-deficient tumor models. A, LoVo tumor xenograft volume in mice treated with RP-3500 orally once daily × 17 days. Results are expressed as mean ± SEM, N = 10/group. a One mouse sacrificed due to body weight loss on day 12. B, Tumor volume of a human gastric cancer PDX A with a biallelic loss of ATM in mice treated with RP-3500 at 5 and 10 mg/kg once daily x 28 days. Results expressed as mean ± SEM, N = 10/group. Statistical significance relative to vehicle control for A and B established by one-way ANOVA with Fisher LSD test; ** P < 0.01; **** P < 0.0001. C, Proportion of pCHK1 (Ser345) inhibition relative to circulating free RP-3500 plasma levels. Tumors and plasma sampled at 1 and 3 hours after RP-3500 administration. The pCHK1/total CHK1 signal is represented relative to vehicle-treated tumors. D, Free circulating plasma concentrations of RP-3500 over time in SCID mice. Green, measured concentrations; red, simulated PK at 5 mg/kg. Horizontal line indicates in vivo LoVo tumor pCHK1 IC 80 determined by nonlinear curve fit of C . Vertical grey bar indicates window of duration over IC 80 at the MED (5–7 mg/kg). h, hours. E, pKAP1 (Ser824) in LoVo tumors from mice treated with RP-3500 once daily x 7 days and harvested 24 hours after the last dose. pKAP1/total KAP1 quantified by immunoblot are represented as fold increase over vehicle control signal. F, Quantitative γH2AX and pKAP1 staining of tissue sections from the gastric PDX-bearing mice treated with RP-3500 once daily for 3 days harvested 24 hours after the last dose. PD, pharmacodynamics.

Journal: Molecular Cancer Therapeutics

Article Title: RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

doi: 10.1158/1535-7163.MCT-21-0615

Figure Lengend Snippet: RP-3500 is efficacious as a single agent in ATM-deficient tumor models. A, LoVo tumor xenograft volume in mice treated with RP-3500 orally once daily × 17 days. Results are expressed as mean ± SEM, N = 10/group. a One mouse sacrificed due to body weight loss on day 12. B, Tumor volume of a human gastric cancer PDX A with a biallelic loss of ATM in mice treated with RP-3500 at 5 and 10 mg/kg once daily x 28 days. Results expressed as mean ± SEM, N = 10/group. Statistical significance relative to vehicle control for A and B established by one-way ANOVA with Fisher LSD test; ** P < 0.01; **** P < 0.0001. C, Proportion of pCHK1 (Ser345) inhibition relative to circulating free RP-3500 plasma levels. Tumors and plasma sampled at 1 and 3 hours after RP-3500 administration. The pCHK1/total CHK1 signal is represented relative to vehicle-treated tumors. D, Free circulating plasma concentrations of RP-3500 over time in SCID mice. Green, measured concentrations; red, simulated PK at 5 mg/kg. Horizontal line indicates in vivo LoVo tumor pCHK1 IC 80 determined by nonlinear curve fit of C . Vertical grey bar indicates window of duration over IC 80 at the MED (5–7 mg/kg). h, hours. E, pKAP1 (Ser824) in LoVo tumors from mice treated with RP-3500 once daily x 7 days and harvested 24 hours after the last dose. pKAP1/total KAP1 quantified by immunoblot are represented as fold increase over vehicle control signal. F, Quantitative γH2AX and pKAP1 staining of tissue sections from the gastric PDX-bearing mice treated with RP-3500 once daily for 3 days harvested 24 hours after the last dose. PD, pharmacodynamics.

Article Snippet: The LoVo tumor IC 80 for pCHK1(Ser345) was determined by a nonlinear least-squares regression to a normalized dose-response four-parameter fit model (GraphPad Prism v9).

Techniques: Control, Inhibition, In Vivo, Western Blot, Staining